daprodustat (Jesduvroq) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW
  • Now
Daprodustat, sold under the brand name Duvroq among others, is a medication that is used for the treatment of anemia due to chronic kidney disease. It is a hypoxia-inducible factor prolyl hydroxylase inhibitor. It is taken by mouth.   Wikipedia

Chemistry

  • SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C3CCCCC3)C1=O
  • InChIKey: RUEYEZADQJCKGV-UHFFFAOYSA-N
  • Mol. Mass: 393.44
  • ALogP: 1.26
  • ChEMBL Molecule:
    daprodustat  
More Chemistry

Pharmacology

Alternative names

1278863a | daprodustat | gsk1278863

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Kidney Failure, Chronic

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Anemia (Phase 4)

Aspergillosis, Allergic Bronchopulmonary (Phase 3)

Kidney Diseases (Phase 4)

Peripheral Vascular Diseases (Phase 2)

Renal Insufficiency, Chronic (Phase 4)

Surgical Procedures, Operative (Phase 2)

Tendon Injuries (Phase 1)

Wound Healing (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 40
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue